openPR Logo
Press release

Epilepsy Clinical Trials 2024: EMA, PDMA, FDA Approvals, Therapies, Medication, Pipeline, Treatment and Companies by DelveInsight | Takeda, Abbott, GlaxoSmithKline, Johnson & Johnson, Novartis, Pfizer, Sanofi, more

10-30-2024 04:00 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Epilepsy Clinical Trials

Epilepsy Clinical Trials

(Albany, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Epilepsy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Epilepsy Market.

The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report: https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Epilepsy Pipeline Report:
• Epilepsy Companies across the globe are diligently working toward developing novel Epilepsy treatment therapies with a considerable amount of success over the years.
• Epilepsy companies working in the treatment market are Receptor Life Sciences, Cerebral Therapeutics, Equilibre Biopharmaceuticals, Cerevel Therapeutics, Elium Therapeutics, CombiGen, Ovid Therapeutics, Otsuka Pharmaceutical Co.,Ltd., SK Biopharmaceuticals, Engrail Therapeutics, Amzell, Xenon Pharmaceuticals Inc., and others, are developing therapies for the Epilepsy treatment
• Emerging Epilepsy therapies in the different phases of clinical trials are- RLS103, CT-010, EQU 001, Darigabat, Kv7 Program, CG 01, OV329, OPC-214870, SKL24741, ENX-101, AMZ002, XEN496, and others are expected to have a significant impact on the Epilepsy market in the coming years.
• In January 2024, US-based biotech company Longboard Pharmaceuticals has reported promising topline results from the Phase Ib/IIa study of LP352 (bexicaserin) for treating developmental and epileptic encephalopathies (DEEs). The randomized, double-blind, placebo-controlled PACIFIC trial (NCT05364021) included 52 patients with DEEs to assess the safety and efficacy of LP352 at doses of 6mg, 9mg, and 12mg three times daily compared to a placebo. The trial's primary endpoint was the median change in countable motor seizure frequency, with LP352-treated patients experiencing a 53.3% reduction versus a 20.8% reduction in the placebo group.
• In January 2023, Amzell has commenced a randomized, open-label study aimed at assessing the superiority of AMZ002 in treating infantile spasms, a rare form of epilepsy. The primary objective of this study is to compare the efficacy and safety of AMZ002 with Vigabatrin in individuals newly diagnosed with infantile spasms (IS).
• In March 2022, Lupin has obtained approval from the United States Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Vigabatrin. This anti-epileptic medication is offered in the form of an oral solution USP (500 mg).

Epilepsy Overview
A chronic neurological illness called epilepsy is typified by recurrent, frequent seizures that cause atypical behavior. Because the causes, severity, and types of seizures vary, it may be classified as a spectrum disorder. The disorder known as epilepsy is characterized by abnormal or excessive electrical discharges from brain cells that impair brain function.

Get a Free Sample PDF Report to know more about Epilepsy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Epilepsy Drugs Under Different Phases of Clinical Development Include:
• RLS103: Receptor Life Sciences
• CT-010: Cerebral Therapeutics
• EQU 001: Equilibre Biopharmaceuticals
• Darigabat: Cerevel Therapeutics
• Kv7 Program: Elium Therapeutics
• CG 01: CombiGen
• OV329: Ovid Therapeutics
• OPC-214870: Otsuka Pharmaceutical Co.,Ltd.
• SKL24741: SK Biopharmaceuticals
• ENX-101: Engrail Therapeutics
• AMZ002: Amzell
• XEN496: Xenon Pharmaceuticals Inc.

Epilepsy Route of Administration
Epilepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Epilepsy Molecule Type
Epilepsy Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Epilepsy Pipeline Therapeutics Assessment
• Epilepsy Assessment by Product Type
• Epilepsy By Stage and Product Type
• Epilepsy Assessment by Route of Administration
• Epilepsy By Stage and Route of Administration
• Epilepsy Assessment by Molecule Type
• Epilepsy by Stage and Molecule Type

DelveInsight's Epilepsy Report covers around 90+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Epilepsy product details are provided in the report. Download the Epilepsy pipeline report to learn more about the emerging Epilepsy therapies
https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Epilepsy Therapeutics Market include:
Key companies developing therapies for Epilepsy are - Novartis AG, Pfizer, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Abbott Laboratories, GlaxoSmithKline PLC, Johnson & Johnson, Sunovion Pharmaceuticals Inc., UCB S.A., Sun Pharmaceutical, GW Pharmaceuticals plc, H. Lundbeck A/S, Alkem Labs., Eisai Co., and others.

Epilepsy Pipeline Analysis:
The Epilepsy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Epilepsy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epilepsy Treatment.
• Epilepsy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Epilepsy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Epilepsy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Epilepsy drugs and therapies
https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Epilepsy Pipeline Market Drivers
• Rising awareness and strategic alliance, increasing launch of novel drugs, high burden of epilepsy are some of the important factors that are fueling the Epilepsy Market.

Epilepsy Pipeline Market Barriers
• However, loss of patent protection for branded drugs, high cost of treatment and other factors are creating obstacles in the Epilepsy Market growth.

Scope of Epilepsy Pipeline Drug Insight
• Coverage: Global
• Key Epilepsy Companies: Receptor Life Sciences, Cerebral Therapeutics, Equilibre Biopharmaceuticals, Cerevel Therapeutics, Elium Therapeutics, CombiGen, Ovid Therapeutics, Otsuka Pharmaceutical Co.,Ltd., SK Biopharmaceuticals, Engrail Therapeutics, Amzell, Xenon Pharmaceuticals Inc., and others
• Key Epilepsy Therapies: RLS103, CT-010, EQU 001, Darigabat, Kv7 Program, CG 01, OV329, OPC-214870, SKL24741, ENX-101, AMZ002, XEN496, and others
• Epilepsy Therapeutic Assessment: Epilepsy current marketed and Epilepsy emerging therapies
• Epilepsy Market Dynamics: Epilepsy market drivers and Epilepsy market barriers

Request for Sample PDF Report for Epilepsy Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Epilepsy Report Introduction
2. Epilepsy Executive Summary
3. Epilepsy Overview
4. Epilepsy- Analytical Perspective In-depth Commercial Assessment
5. Epilepsy Pipeline Therapeutics
6. Epilepsy Late Stage Products (Phase II/III)
7. Epilepsy Mid Stage Products (Phase II)
8. Epilepsy Early Stage Products (Phase I)
9. Epilepsy Preclinical Stage Products
10. Epilepsy Therapeutics Assessment
11. Epilepsy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Epilepsy Key Companies
14. Epilepsy Key Products
15. Epilepsy Unmet Needs
16 . Epilepsy Market Drivers and Barriers
17. Epilepsy Future Perspectives and Conclusion
18. Epilepsy Analyst Views
19. Appendix
20. About DelveInsight

Trending Reports:
• Epithelioid Sarcoma Market: https://www.delveinsight.com/report-store/epithelioid-sarcoma-market
• Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/atrial-fibrillation-market
• Emesis Market: https://www.delveinsight.com/report-store/emesis-market
• Lymphocytopenia Market: https://www.delveinsight.com/report-store/lymphocytopenia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Alstrom Syndrome Market: https://www.delveinsight.com/report-store/alstrom-syndrome-epidemiology-forecast
• Walking Impairment In Multiple Sclerosis Market: https://www.delveinsight.com/report-store/walking-impairment-in-multiple-sclerosis-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Advanced Recurrent Ovarian Cancer Market: https://www.delveinsight.com/report-store/advanced-recurrent-ovarian-cancer-market
• Primary Progressive Multiple Sclerosis Ppms Market: https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-pipeline-insight
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-market
• Surgical Stapling Devices Market: https://www.delveinsight.com/report-store/surgical-stapling-devices-market
• Biochips Market: https://www.delveinsight.com/blog/biochips-market-landscape
• Radioligand Therapies Market: https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast
• Goitre Market: https://www.delveinsight.com/report-store/goitre-market
• Pharma Competitive Intelligence: https://www.delveinsight.com/blog/competitive-intelligence-in-healthcare-sector
• Post-bariatric Hypoglycemia Market: https://www.delveinsight.com/report-store/post-bariatric-hypoglycemia-market
• Hemophilia With Inhibitor Market: https://www.delveinsight.com/report-store/hemophilia-a2030-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Primoridal Dwarfism Market: https://www.delveinsight.com/report-store/primordial-dwarfism-market
• Dermal Mycosis Market: https://www.delveinsight.com/report-store/dermal-mycosis-pipeline-insight
• Penicillinbinding Proteins Market: https://www.delveinsight.com/report-store/penicillin-binding-proteins-market
• Adenoid Cystic Carcinoma Market: https://www.delveinsight.com/report-store/adenoid-cystic-carcinom-market
• Hereditary Spastic Paraplegias Market: https://www.delveinsight.com/report-store/hereditary-spastic-paraplegias-market
• Ventricular Dysfunction Market: https://www.delveinsight.com/report-store/ventricular-dysfunction-market
• Alagille Syndrome Market: https://www.delveinsight.com/report-store/alagille-syndrome-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Implantable Infusion Pumps Market: https://www.delveinsight.com/report-store/implantable-infusion-pumps-market
• Bone Densitometers Market: https://www.delveinsight.com/report-store/bone-densitometers-market
• Hpv-induced Cancers Market: https://www.delveinsight.com/report-store/hpv-induced-cancers-market
• Cerebral Vein Thrombosis Market: https://www.delveinsight.com/report-store/cerebral-vein-thrombosis-market
• Contraceptive Devices Market: https://www.delveinsight.com/report-store/contraceptive-devices-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Ankylosing Spondylitis Bekhterevs Disease Market: https://www.delveinsight.com/report-store/ankylosing-spondylitis-as-market
• Atrophic Vaginitis Market: https://www.delveinsight.com/report-store/atrophic-vaginitis-market
• Diffuse Cutaneous Systemic Sclerosis Market: https://www.delveinsight.com/report-store/diffuse-cutaneous-systemic-sclerosis-dcssc-market
• Idiopathic Membranous Nephropathy Market: https://www.delveinsight.com/report-store/idiopathic-membranous-nephropathy-imn-market
• Intrahepatic Cholangiocarcinoma Market: https://www.delveinsight.com/report-store/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast
• Acute Gout Flare Market: https://www.delveinsight.com/report-store/acute-gout-flare-market
• Aids Related Kaposi's Sarcoma Market: https://www.delveinsight.com/report-store/aids-related-kaposis-sarcoma-market
• Chronic Idiopathic Urticaria Market: https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-market
• Crohns Disease Cd Market: https://www.delveinsight.com/report-store/crohns-disease-cd-market
• Helicobacter Pylori Infections Market: https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market
• Juvenile Rheumatoid Arthritis Market: https://www.delveinsight.com/report-store/juvenile-rheumatoid-arthritis-market
• Acromegaly Market: https://www.delveinsight.com/report-store/acromegaly-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Chronic Plaque Psoriasis Market: https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
• Post-transplant Lymphoproliferative Disease Market: https://www.delveinsight.com/report-store/post-transplant-lymphoproliferative-disorder-market
• Wet-age Related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Central Retinal Venous Occulsion Market: https://www.delveinsight.com/report-store/retinal-vein-occlusion-market
• Gastric Neuroendocrine Tumors Market: https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market
• Post Traumatic Stress Disorder Market: https://www.delveinsight.com/report-store/post-traumatic-stress-disorder-ptsd-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Epilepsy Clinical Trials 2024: EMA, PDMA, FDA Approvals, Therapies, Medication, Pipeline, Treatment and Companies by DelveInsight | Takeda, Abbott, GlaxoSmithKline, Johnson & Johnson, Novartis, Pfizer, Sanofi, more here

News-ID: 3714838 • Views:

More Releases from DelveInsight Business Research

Fabry Disease Market to grow at a CAGR of ~6% by 2032, analyzes DelveInsight | Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, etc
Fabry Disease Market to grow at a CAGR of ~6% by 2032, analyzes DelveInsight | P …
(Albany, USA) DelveInsight's "Fabry Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Fabry Disease, historical and forecasted epidemiology as well as the Fabry Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Fabry Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Fabry Disease market
Secondary Hyperparathyroidism Drugs Market 2032: Clinical Trials, FDA Approvals, Prevalence, Therapies and Companies by DelveInsight | Amgen, OPKO Health, AbbVie, Shire Plc, Roche AG, Sanofi, Kyowa Hakko Kirin, Astellas Pharma, Leo Pharma A/S, more
Secondary Hyperparathyroidism Drugs Market 2032: Clinical Trials, FDA Approvals, …
(Albany, USA) DelveInsight's "Secondary Hyperparathyroidism Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Secondary Hyperparathyroidism, historical and forecasted epidemiology as well as the Secondary Hyperparathyroidism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Secondary Hyperparathyroidism market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Secondary Hyperparathyroidism market
Atypical Hemolytic Uremic Syndrome Drugs Market 2034: Prevalence, FDA Approvals, Clinical Trials, Therapies and Companies by DelveInsight | Omeros Corporation, Akari Therapeutics, Alexion Pharmaceuticals, Novartis Pharmaceuticals, Hoffmann-La Roche
Atypical Hemolytic Uremic Syndrome Drugs Market 2034: Prevalence, FDA Approvals, …
(Albany, USA) DelveInsight's "Atypical Hemolytic Uremic Syndrome Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Atypical Hemolytic Uremic Syndrome, historical and forecasted epidemiology as well as the Atypical Hemolytic Uremic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Atypical Hemolytic Uremic Syndrome market report provides current treatment practices, emerging drugs, the market share of the individual therapies,
Alpha-1 Antitrypsin Deficiency Clinical Trials 2024: FDA Approvals, Medication, Treatment Market, Therapies, MOA, ROA, Companies by DelveInsight
Alpha-1 Antitrypsin Deficiency Clinical Trials 2024: FDA Approvals, Medication, …
DelveInsight's, "Alpha1-Antitrypsin Deficiency Pipeline Insight 2024" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the Alpha1-Antitrypsin Deficiency pipeline landscape. It covers the Alpha-1 Antitrypsin Deficiency pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Alpha-1 Antitrypsin Deficiency pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Request a sample

All 5 Releases


More Releases for Epilepsy

Epilepsy Market Synthesis and Opportunity Assessment 2030
Epilepsy - Market Insight, Epidemiology And Market Forecast -2030: This report delivers an in-depth understanding of the Epilepsy, historical and forecasted epidemiology as well as the Epilepsy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Epilepsy market report provides current treatment practices, emerging drugs, Epilepsy market share of the individual therapies, current and forecasted Epilepsy market Size from 2017 to 2030 segmented
Rising Instances of Pediatric Epilepsy to Pave Novel Growth Avenues in Epilepsy …
Owing to large scale prevalence of epilepsy cases, inclusive of pediatric epilepsy, the market for epilepsy drugs is likely to remain agile in the coming years. Prevalent amongst both male and female demographics alike, epilepsy is a critical condition that affects the brain both partially as well as in whole. Lucrative reimbursement policies, coupled with growing patient awareness about novel therapeutics are likely to reflect favorably on the growth curve
World Congress on Epilepsy and Neuronal Synchronization
Inculcate the latent knowledge in Epilepsy and Neuronal synchrony May 14, 2018: Pulsus Group, host of World Congress on Epilepsy and Neuronal Synchronization, the Conference that discusses the Advanced diagnosis of Epilepsy. Epilepsy 2018 slated during October 15- 16, 2015 at London, UK will schedule and coordinate all meetings with our Editorial Board Members and other experts in the Neurology, Neuropsychiatry & Neuropathology fields across the world. The Epilepsy conference scientific
Epilepsy Therapeutic Pipeline Market Review, 2026
Summary Epilepsy is a brain disorder characterized by recurrent and unpredictable seizures that are caused by sudden, disorderly, and excessive neuronal activity in the brain. It is one of the most common neurological conditions globally. Epilepsy can start at any age and can be a life-long condition. It is diagnosed after a patient has suffered at least one epileptic seizure and is referred to a specialist, where a description of the
Epilepsy - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Epilepsy - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epilepsy - Pipeline Review, H2 2017, provides an overview of the Epilepsy (Central Nervous System) pipeline landscape. Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in the
H2 Epilepsy Market Pipeline Review 2017
"The Report Epilepsy - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epilepsy - Pipeline Review, H2 2017, provides an overview of the Epilepsy (Central Nervous System) pipeline landscape. Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in